Literature DB >> 26323190

Who may benefit from preoperative breast MRI? A single-center analysis of 1102 consecutive patients with primary breast cancer.

Manuel Debald1, Alina Abramian2, Lisa Nemes2, Michael Döbler2, Christina Kaiser2, Mignon-Denise Keyver-Paik2, Claudia Leutner3, Tobias Höller4, Michael Braun2,5, Christiane Kuhl6, Walther Kuhn2, Hans H Schild3.   

Abstract

Several authors question the potential benefit of preoperative magnetic resonance imaging (MRI) against the background of possible overdiagnosis, false-positive findings, and unnecessary resections in patients with newly diagnosed breast cancer. In order to reveal a better selection of patients who should undergo preoperative MRI after histological confirmed breast cancer, the present analysis was implemented. We aimed to evaluate the influence of preoperative breast MRI in patients with newly diagnosed breast cancer to find subgroups of patients that are most likely to benefit from preoperative MRI by the detection of occult malignant foci. A total of 1102 consecutive patients who underwent treatment for primary breast cancer between 2002 and 2013 were retrospectively analyzed. All patients underwent triple assessment by breast ultrasound, mammography, and bilateral breast MRI. MRI findings not seen on conventional imaging that suggested additional malignant disease was found in 344 cases (31.2 %). Histological confirmed malignant foci were found in 223 patients (20.2 %) within the index breast and in 28 patients (2.5 %) in the contralateral breast. The rate of false-negative biopsies was 31 (2.8 %) and 62 (5.6 %), respectively. Premenopausal women (p = 0.024), lobular invasive breast cancer (p = 0.02) as well as patients with high breast density [American College of Radiology (ACR) 3 + 4; p = 0.01] were significantly associated with additional malignant foci in the index breast. Multivariate analysis confirmed lobular histology (p = 0.041) as well as the co-factors "premenopausal stage" and "high breast density (ACR 3+4)" (p = 0.044) to be independently significant. Previous studies revealed that breast MRI is a reliable tool for predicting tumor extension as well as for the detection of additional ipsilateral and contralateral tumor foci in histological confirmed breast cancer. In the present study, we demonstrate that especially premenopausal patients with high breast density as well as patients with lobular histology seem to profit from preoperative MRI.

Entities:  

Keywords:  Breast cancer; MRI; Preoperative management; Surgery

Mesh:

Substances:

Year:  2015        PMID: 26323190     DOI: 10.1007/s10549-015-3556-3

Source DB:  PubMed          Journal:  Breast Cancer Res Treat        ISSN: 0167-6806            Impact factor:   4.872


  10 in total

1.  Incidentally detected enhancing lesions found in breast MRI: analysis of apparent diffusion coefficient and T2 signal intensity significantly improves specificity.

Authors:  Otso Arponen; Amro Masarwah; Anna Sutela; Mikko Taina; Mervi Könönen; Reijo Sironen; Juhana Hakumäki; Ritva Vanninen; Mazen Sudah
Journal:  Eur Radiol       Date:  2016-04-25       Impact factor: 5.315

2.  Impact of value based breast cancer care pathway implementation on pre-operative breast magnetic resonance imaging utilization.

Authors:  Devina K S McCray; Stephen R Grobmyer; Holly J Pederson
Journal:  Gland Surg       Date:  2017-02

3.  The Yield of Pre-operative Breast MRI in Patients According to Breast Tissue Density.

Authors:  Jean M Seely; Leslie Lamb; Neera Malik; Jacqueline Lau
Journal:  Eur Radiol       Date:  2015-11-30       Impact factor: 5.315

4.  Incremental cancer detection using breast ultrasonography versus breast magnetic resonance imaging in the evaluation of newly diagnosed breast cancer patients.

Authors:  Hongying He; Jeri S Plaxco; Wei Wei; Lei Huo; Rosalind P Candelaria; Henry M Kuerer; Wei T Yang
Journal:  Br J Radiol       Date:  2016-07-07       Impact factor: 3.039

5.  Breast MR imaging for the assessment of residual disease following initial surgery for breast cancer with positive margins.

Authors:  Julia Krammer; Elissa R Price; Maxine S Jochelson; Elizabeth Watson; Melissa P Murray; Stefan O Schoenberg; Elizabeth A Morris
Journal:  Eur Radiol       Date:  2017-05-31       Impact factor: 5.315

6.  Association of Magnetic Resonance Imaging and a 12-Gene Expression Assay With Breast Ductal Carcinoma In Situ Treatment.

Authors:  Constance D Lehman; Constantine Gatsonis; Justin Romanoff; Seema A Khan; Ruth Carlos; Lawrence J Solin; Sunil Badve; Worta McCaskill-Stevens; Ralph L Corsetti; Habib Rahbar; Derrick W Spell; Kenneth B Blankstein; Linda K Han; Jennifer L Sabol; John R Bumberry; Ilana Gareen; Bradley S Snyder; Lynne I Wagner; Kathy D Miller; Joseph A Sparano; Christopher Comstock
Journal:  JAMA Oncol       Date:  2019-07-01       Impact factor: 31.777

7.  Role of magnetic resonance imaging in the planning of breast cancer treatment strategies: comparison with conventional imaging techniques.

Authors:  Luciana Karla Lira França; Almir Galvão Vieira Bitencourt; Hugo Lamartine Souza Paiva; Caroline Baptista Silva; Nara Pacheco Pereira; Jociana Paludo; Luciana Graziano; Camila Souza Guatelli; Juliana Alves de Souza; Elvira Ferreira Marques
Journal:  Radiol Bras       Date:  2017 Mar-Apr

8.  A survey by the European Society of Breast Imaging on the utilisation of breast MRI in clinical practice.

Authors:  Paola Clauser; Ritse Mann; Alexandra Athanasiou; Helmut Prosch; Katja Pinker; Matthias Dietzel; Thomas H Helbich; Michael Fuchsjäger; Julia Camps-Herrero; Francesco Sardanelli; Gabor Forrai; Pascal A T Baltzer
Journal:  Eur Radiol       Date:  2017-11-22       Impact factor: 5.315

9.  Impact of breast magnetic resonance imaging on the locoregional staging and management of breast cancer.

Authors:  Luciana Karla Lira França; Almir Galvão Vieira Bitencourt; Fabiana Baroni Alves Makdissi; Carla Curi; Juliana Alves de Souza; Elvira Ferreira Marques
Journal:  Radiol Bras       Date:  2019 Jul-Aug

10.  Antibody-Guided In Vivo Imaging for Early Detection of Mammary Gland Tumors.

Authors:  Laura Jeffords Moore; Lopamudra Das Roy; Ru Zhou; Priyanka Grover; Shu-Ta Wu; Jennifer M Curry; Lloye M Dillon; Priya M Puri; Mahboubeh Yazdanifar; Rahul Puri; Pinku Mukherjee; Didier Dréau
Journal:  Transl Oncol       Date:  2016-08       Impact factor: 4.243

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.